Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
Authors: B Heyman, A D Volkheimer, J B Weinberg
Journal: Blood Cancer Journal (2016)

B-cell chronic lymphocytic leukemia is a clinically, genetically and molecularly heterogonous malignancy. 1 During normal B-cell maturation, chromosomal recombination of the immunoglobulin heavy chain V (variable), D (diversity) and J (junctional) gene, and immunoglobulin kappa and lambda light chain V-J gene rearrangement provides the basis for the tremendous immunologic diversity of B cells. 1 Upon encounter with cognate antigen, B cells can undergo a process of somatic hypermutation during the germinal center reaction in which the recombined VDJ acquire point mutations, thus increasing the affinity for the antigen.Patients with unmutated IGHV genes have inferior clinical outcomes when compared with patients with mutated IGHV. 2,3hromosomal VDJ gene rearrangement is a stochastic, yet highly regulated process.Each B cell undergoes a distinct rearrangement, yielding expression of a unique B cell receptor (BCR).Through the process of allelic exclusion, if the first allelic VDJ rearrangement is productive, VDJ rearrangement does not occur on the second allele.If the first rearrangement is nonproductive, the second allele undergoes VDJ rearrangement to produce a functional BCR.The same principle is followed for light chain rearrangement.The cell undergoes apoptosis if no functional rearrangements are made.Allelic rearrangements can also occur via noncompatible pair of heavy or light chain rearrangement or rescue of deleterious mutations during somatic hypermutation. 4 Typically, VDJ rearrangement occurs to produce one productive IGHV.However, some chronic lymphocytic leukemia (CLL) cells may lack allelic exclusion and produce two productive rearrangements. 5,6assenti and Kipps 5 reported that doubly productive rearrangements were present in 6 of 108 (5%) samples examined by sequencing complementary DNA derived from patient messenger RNA.Langerak et al. 7 identified 374/2526 (14.8%) of cases with double rearrangements when analyzing DNA and 61/1628 (3.8%) of cases with doubly productive rearrangements when using complementary DNA.Risk, prognosis and outcome where not assessed in studies of Langerak et al. 7 Cerny et al. 8 assessed the DNA of CLL patients and compared a cohort of 17 patients having biallelic IGHV rearrangements with 37 patients having single IGHV rearrangements. 8They found that at 3 years, neither OS nor the risk of disease progression was different between the two groups.They did not assess the mutation status of each rearrangement.We used CLL cell DNA to detect the mutation status of both the productive and nonproductive IGHV rearrangements present in leukemic cells in a prospectively ascertained CLL cohort with treatment and survival outcomes.Adult patients with CLL from the Duke University and Durham Veterans Affairs (VA) Medical Centers were enrolled into a longitudinal cohort study between 1999 and 2014.CLL diagnosis and Rai staging were according to the NCI Working Group criteria. 9Patients were followed clinically for disease progression, need for treatment or death.Primary end points for the study were time to treatment (TTT) and overall survival (OS).OS was from the time of